Bull. Fac. Ph. Th. Cairo Univ., Vol. 16, No. (1) Jan. 2011
81
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
Intsar S.Waked, Samah H.Nagib and Marwa M. Eid
Department of Surgery, Faculty of Physical Therapy, Cairo University, Giza, Egypt.
ABSTRACT
The purpose of this study was to evaluate the
effectiveness of medium versus low dose ultraviolet
A1 in the treatment of childhood localized
scleroderma (morphea). Thirty patients with
localized scleroderma (LS) referred by
dermatologist were participated in this study.
Their age ranged from 6 to 13 years. Patients were
classified into two groups of equal number; group
(1) received UVA1 (340-400 nm) phototherapy at
a medium dose of 40 J/cm2 while group (2)
received UVA1 (340-400 nm) phototherapy at a
low dose of 20 J/cm2 for three times a week for 10
weeks. Skin thickness, echogenicity and skin
hardness were measured at the beginning and after
10 weeks of treatment. Results of this study
revealed a highly significant differences between
both
groups,
regarding
skin
thickness,
echogenicity and skin hardness (P values < 0.05).
On conclusion, medium dose UVA1 is more
effective than low dose UVA1 in the treatment of
childhood morphea.
Key words: Localized scleroderma, morphea,
ultraviolet A1, medium dose UVA1, low dose
UVA1, ultrasonography, durometery, skin
thickness, echogenicity, skin hardness.
INTRODUCTION
S
cleroderma
is
a
broad
term
encompassing both localized and
systemic
sclerosis.
Localized
scleroderma (LS) is a cutaneous limited
fibrosis that manifests as plaque morphea,
generalized morphea, linear scleroderma, and
deep morphea15,33. LS is the most common
form of scleroderma in the pediatric age range.
Systemic scleroderma (sclerosis) can manifest
as either limited or diffuse disease which most
commonly in adult age2,8,41.
Localized scleroderma (LS) also known
(morphea) denotes a spectrum of conditions
characterized by circumscribed fibrotic areas
involving different levels of the dermis,
subcutis, and sometimes underlying soft tissue
and bone. Although the clinical course of the
disease is often benign, widespread lesions and
disabling joint contractures may lead to
significant complications. The pathogenesis of
the different types of localized scleroderma is
still unknown3,23. Numerous therapeutic agents
have been reported to be effective in this
disease spectrum, but controlled studies are
rare17,43.
Localized scleroderma (LS) or morphea
is characterized by collagen accumulation and
excessive sclerosis of the skin. The major
complaints are tightness and itching and the
disease is often complicated by contractures
and cosmetic disfigurement. The underlying
pathogenesis of morphea is not completely
understood at this time, but ultimately results
in an imbalance of collagen production and
destruction6.
Morphea, is a thickening and hardening
of the skin and subcutaneous tissues. It
includes specific conditions ranging from very
small plaques only involving the skin to
widespread disease causing functional and
cosmetic deformities39. Morphea involves
isolated patches of hardened skin and
discriminates from systemic sclerosis by its
supposed lack of internal organ involvement42.
Morphea mainly involves women with a
women: men ratio of 3:1. There is a higher
frequency of family history of autoimmune
diseases in patients with morphea30. Tests for
autoantibodies associated with morphea have
shown results in higher frequencies of antihistone
and
anti-topoisomerase
IIa
antibodies16.
Good outcome measures are required to
determine whether a therapy is effective, both
in routine clinical practice and in experimental
clinical trials12. In disorders of skin thickening
such as morphea and scleroderma, more
commonly used outcome measures that use a
subjective score based on palpated skin
thickening are fraught with error. By contrast,
measurements made by ultrasound have great
promise as outcome measures that are
quantitative,
valid,
reproducible,
and
34
responsive .
82
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
Ultrasound scanning is becoming an
important diagnostic tool in dermatology. The
major advantages of this technique are its non
invasive, non-ionizing nature and its relatively
low cost10. It shows great promise for the
evaluation of localized scleroderma (LS).
Disease-related structural changes, such as
tissue thickening, atrophy, and architectural
alterations, can be readily detected using
ultrasound. High spatial resolution enables
monitoring of changes in tissue thickness,
echogencity over the course of disease and
treatment24.
Additionally, measurement of skin
hardness by durometry may help improve the
evaluation of therapeutic agents by providing
greater intraobserver reliability than physical
examination skin scoring11,37. Durometers
measure skin hardness in patients with
scleroderma on a continuous scale at each site,
allowing for detection of smaller changes.
Durometers are reliable, simple, accurate,
scalable, demonstrate good sensitivity to
change compared with traditional skin scoring,
and reflect patients' self-assessments of their
disease1,7,27.
Numerous treatment modalities, some
with potentially hazardous side effects, are
currently used for morphea (M) and systemic
sclerosis (SS) with limited success9. The
ultraviolet (UV) fraction of the solar spectrum
is the most biologically active because it is
almost completely absorbed by the skin.
Today, different forms of UVA phototherapy
are widely used and have subsequently
developed into a treatment modality of
importance within the field of dermatology
and rheumatology at least as an adjunctive
treatment and as a successful alternative in the
treatment of skin manifestations of connective
tissue diseases and related disorders32.
Ultraviolet (UV) therapy has once more
demonstrated its high value in the poor
therapeutic armamentarium of sclerotic skin
diseases. The introduction of psoralen and
UVA in 1994 was recognized a cornerstone in
the
management
of
LS.
However,
disadvantages of psoralen and UVA such as
possible gastrointestinal and carcinogenic
effects have led to an intense search for LS21.
Recent studies suggest that ultraviolet (UV)
A1 phototherapy is an effective treatment for
localized scleroderma (LS); however, the
optimum UVA1 dose remains to be
determined40. The purpose of study was to
compare the effectiveness of medium versus
low dose UVA1 in the treatment of childhood
morphea.
PATIENTS AND METHODS
Subjects
This study was carried out on 30 patients
(18 girls, 12 boys) with active localized
scleroderma. They were recruited from the
outpatient clinics of Dermatology, EL- Matria
Teaching Hospital, Cairo, Egypt. Signed
informed consent was obtained from each
participant before enrollment in the study. The
history and clinical examination were done for
all patients and diagnosis of LS was made
according to criteria proposed by American
college of rheumatology for classification of
scleroderma31. Features reported by clinicians
as indicative of active disease included
erythema, warmth, violaceous color, new
lesion, expansion of lesion, and induration25.
Reasons for exclusion were patients had
a history of photosensitivity, skin malignancy,
using potentially glucocorticoids, phototoxic
or immunosuppressive medication, also
participation in another clinical research study
within the last 30 days. The criteria for entry
into the treatment were; The patient's age
ranged from 6 to 13 years. Elapsed time since
the beginning of the LS disease was less than
3 years. Types of LS (morphea) included were
plaque, generalized and mixed types. All
subjects were participated in single blind,
randomized, controlled trial. A complete
history and physical exam, complete blood
count, urinalysis and antinuclear antibody
(ANA) were done for all patients. All
laboratory testing was negative except ANA
positivity was most frequent in mixed and
generalized types.
A computerized random number list was
generated and the subject allocation sequence
was created from the list. Sclerotic plaques
were assessed by ultrasound and the durometer
at the baseline and after 10 weeks of treatment.
Following the assessments, the patients were
assigned into 2 groups of equal number. Group
(1):
received
UVA1
(340-400
nm)
Bull. Fac. Ph. Th. Cairo Univ., Vol. 16, No. (1) Jan. 2011
phototherapy at a medium dose of 40 J/cm2
three times a week for 10 weeks. thirty
phototherapy sessions resulted in a cumulative
dose of 1200 J/cm2 UVA1 while group (2)
received UVA1 (340-400 nm) phototherapy at
a low dose of 20 J/cm2 three times a week for
10 weeks. thirty phototherapy sessions resulted
in a cumulative dose of 600 J/cm2 UVA1.
Ethical consideration
The
experimental
protocol
was
explained in details for each patient before the
initial assessment and signed informed consent
was obtained from each participant before
enrollment in the study (from their families).
The trial protocol was approved by the
meeting of the department of surgery, faculty
of physical therapy, Cairo university. There
was no harm inflicted on the patients. On the
contrary, all had benefited from the final
results of the study.
Measurements
1- Ultrasonography Measurements:
Throughout this study, skin thickness
and echogenisity were measured using a highresolution ultrasound system dedicated to skin
applications. A Derma Scan C Ver. 3 (Cortex
Technology ApS, Hadsund, Denmark) was
used. The system configuration for this study
operated at 20 MHz and provided a resolution
of 606130 mm (axial&lateral) with 8 mm
penetration.
The system consists of a main unit
accommodating the signal processing and
computing components, a color monitor to
display the two-dimensional recordings and a
handheld B-scanning ultrasound probe.
Transducer of the system was mounted in a
water chamber. The chamber window was
covered with a disposable plastic membrane.
The size of the probe was 19X33 mm and the
scan length 12.1 mm.
There are
a number of variables
namely, race, age, sex, anatomical site, and
time of the day may be relevant for the
outcome of measurements of skin thickness.
Measurements were made at the beginning
and after 10 weeks of treatment.
Measurements were made at each of five skin
sites, over the dorsal aspect of the
interarticular portion of the proximal phalanx
of the right second finger (phalanx), over the
83
area between the metacarpophalangeal joints II
and III of the right hand (hand), over the dorsal
aspect of the right forearm 3 cm proximal of
the wrist (forearm), over the lateral aspect of
the leg 12 cm proximal of the ankle joint (leg),
and over the sternum 2 cm distal from the
upper part of the manubrium (chest)13,19. All
measurements were made before noon. When
imaging, the transducer was positioned
perpendicular to the skin to avoid obliquity
and to prevent errors during determination of
skin thickness. A thick layer of ultrasound gel
is applied to improve near field visibility and
avoid tissue compression, which would alter
measurements of tissue thickness. An
improvement occur after treatment if the
thickness of skin decrease and echogenicity
increase22,24.
2- Durometer measurement:
Skin hardness was measured using
handheld digital durometer (Rex Durometer
Max Hand model 1700, type 0, without a foot
attachment) with a calibrated gauge that
registers linearly divided units on a scale from
0 to 100, that registers the relative degree of
hardness. At the bottom of the durometer,
there is a small, inferior indenter that is
retractable and is responsible for the
measurements registered on the gauge.
For measurements, the durometer was
used at 25°C room temperature and rested by
gravity against the skin; Between readings the
durometer was reset to 0. Measurements were
made at predetermined landmark sites at 9
locations, forearms, upper arms, abdomen,
thighs, and legs. Measurements were made
with the underlying muscles relaxed and the
skin in a horizontal plane. Four consecutive
durometry readings were taken at the same site
and the results were averaged. and the average
of each of these measurements was summed to
give the total durometer score27,37.
Durometer measurements are expressed
in standardized durometer units (DU). Final
hardness is defined as that recorded within 15
second of firm contact of the durometer with
the skin without risk or discomfort. Durometer
scores were recorded before and after 10
weeks of the treatment. Skin hardness may be
affected by skin thickness as well as skin
density, elasticity, and edema. Variability in
durometer readings may result from not
84
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
allowing the entire weight of the durometer to
bear down on the skin, not holding the
durometer perpendicular to the plane of the
skin site, or not positioning the skin
horizontally. Durometers should be checked
for malfunction and recalibration of the
instrument is required. An improvement occur
after treatment if the hardness of skin
decrease40.
Treatment Procedures
The UVA1 irradiation equipment was
used to conduct this study and consisted of a
Waldmann 7001 K cabin with Waldmann
TL10 R low pressure lamps. (Waldmann,
GmbH. Schwenningen, Germany). These
lamps generate UVA1 wavelengths in the 340400 nm range. In addition, infrared irradiation
is
emitted.
However
these
infrared
wavelengths are filtered out by an acrylic glass
screen. The UVA1 irradiation levels are
approximately 35 mW/cm2 and are measured
by a standard intrinsic UV meter. A dose of 20
J/cm2 was achieved in approximately 10
minutes and 20 minutes to achieve 40 J/cm2.
Group (1): received medium-dose (40
J/cm2) UVA1. The frequency of therapy was
three times a week for 10 weeks. thirty
phototherapy sessions resulted in a cumulative
dose of 1200 J/cm2 UVA1. The starting dose
was determined by Fitzpatrick skin type. Also
the minimal erythematus dose (MED) (the
dose of UV-A1 causing just perceptible
erythema) will determined for every subject.
Standard safety precautions, including the use
of protective eyewear, were maintained. Group
(2): received low dose (20 J/cm2). The
frequency of therapy was three times a week
for 10 weeks. thirty phototherapy sessions
resulted in a cumulative dose of 600 J/cm2
UVA1.
Statistical Analysis
Data were expressed as mean ± standard
deviation (SD). Student t test was used to
assess the difference between the studied
parameters (thickness, echogencity and skin
hardness) in two groups. Paired t test was used
to analyze the thickness, echogencity and
hardness of the skin within the group. Analysis
was performed using SPSS/PC software (SPSS
Inc., Chicago, IL, USA). All p values less than
0.05 were considered to be statistically
significant.
RESULTS
Data
concerning
the
patients'
demographic and clinical characteristics
included sex, age, positive family history,
duration of disease, as well as initial skin
thickness, echogenisity and skin hardness
measurement
have been collected at the
beginning of the study. Follow up evaluation
of skin thickness, echogenicity and skin
hardness has been performed after 10 weeks of
treatment.
Demographic characteristics of the patients.
As shown in table (1 and 2), there were
no statistical significant differences (P>0.05)
observed between both groups concerning
general characteristics (age, sex, positive
family history, duration of disease, as well as
initial skin thickness, echogenisity and skin
hardness measurement).
Table (1): Statistical analysis of the demographic characteristics of all patients for both groups (1 and 2).
Age (years)
Sex( female/male)
Type of morphea (plaque:general: mixed)
Positive family History
Duration of disease (months)
ANA positivity
*Non significant
Group (1)
(n=15)
8.60±2.38
8/7
7:5:3
7/15(46%)
18.53±9.1
9/15(60%)
Group (2)
(n=15)
9.40±2.23
10/5
6:4:5
6/15(40%)
18.13±9.78
11⁄15(73%)
P-value
0.351*
0.646*
0.534*
0.717*
0.909*
0.446*
Bull. Fac. Ph. Th. Cairo Univ., Vol. 16, No. (1) Jan. 2011
85
Table (2): Mean initial thickness, echogenicity and skin hardness of patients in both groups.
Group (1)
(n=15)
Initial Thickness (mm)
X±SD
Phalanx
2.69±0.58
Hand
2.30±0.35
Forearm
2.24±0.52
Leg
2.37±0.52
Chest
2.29±0.48
Initial echogenicity (pixels)
Phalanx
17.80±3.94
Hand
21.33±3.49
Forearm
24.8±4.42
Leg
25.53±4.45
Chest
31.60±3.41
Initial skin hardness (DU)
36.13±4.18
X=mean, SD=Standard Deviation P-value=Probability level, *Non-Significant (P>0.05).
Results of group (1):
As shown in table (3) the mean value,
standard deviation and P value of thickness,
echogenicity and skin hardness pre and post
Group (2)
(n=15)
P-value
X±SD
2.72±0.49
2.40±0.39
2.24±0.51
2.20±0.46
2.25±0.41
0.912*
0.467*
0.425*
0.355*
0.809*
18.53±2.33
22.60±3.88
22.93±2.54
24.00±4.14
29.00±6.14
35.00±4.47
0.541*
0.356*
0.264*
0.337*
0.163*
0.480*
treatment for group 1. The results showed
significant differences pre and post treatment
for group1 as P value <0.05.
Table (3): Mean thickness, echogenicity and skin hardness of patients pre and post treatment of group 1.
Pre
X±SD
Thickness (mm)
Phalanx
2.69±0.58
Hand
2.30±0.35
Forearm
2.24±0.52
Leg
2.37±0.52
Chest
2.29±0.48
Echogenicity (pixels)
Phalanx
17.80±3.94
Hand
21.33±3.49
forearm
24.80±4.42
Leg
25.53±4.45
Chest
31.60±3.41
Skin hardness
36.13±4.18
X=mean, SD=Standard Deviation P-value=Probability level
Results of group (2):
As shown in table (4) the mean value,
standard deviation and P value of thickness,
echogenicity and skin hardness pre and post
Post
X±SD
P-value
1.80±0.354
1.58±0.20
1.58±0.24
1.42±0.23
1.48±0.22
0.000*
0.000*
0.000*
0.000*
0.000*
26.23±5.70
31.26±5.20
34.54±3.54
31.66±5.91
42.33±3.58
23.86±4.42
*
highly significant (P<0.05).
0.000*
0.000*
0.000*
0.000*
0.000*
0.000*
treatment for group 2. The results showed
significant differences pre and post treatment
for group 2 as P value <0.05.
Table (4): Mean thickness, echogenicity and skin hardness of patients pre and post treatment of group 2.
Pre
X±SD
Thickness (mm)
Phalanx
2.72±0.49
Hand
2.40±0.39
Forearm
2.24±0.51
Leg
2.20±0.46
Chest
2.25±0.41
Echogenicity (pixels)
Phalanx
18.53±2.33
Hand
22.60±3.88
forearm
22.93±2.54
Leg
24.00±4.14
Chest
29.00±6.14
Skin hardness
35.00±4.47
X=mean, SD=Standard Deviation P-value=Probability level
Post
X±SD
P-value
2.35±0.39
2.22±0.40
2.29 ±0.49
2.13±0.45
2.21±0.42
0.000*
0.02*
0.000*
0.000*
0.012*
20.20±2.11
24.53±3.66
26.20±4.63
25.46±3.85
30.06±6.36
30.60±3.20
* significant (P<0.05).
0.001*
0.000*
0.000*
0.002*
0.001*
0.001*
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
86
Comparative analysis of the mean
differences of skin thickness, echogenicity and
skin hardness between both groups posttreatment.
Table (5) showed the mean differences
of skin thickness, echogenicity and skin
hardness between both groups post treatment.
The results showed that there were highly
statistically significant differences between
both groups at the end of the study with P
value <0.05.
Table (5): Comparative analysis of the mean differences of skin thickness, echogenicity and skin hardness
between both groups post-treatment.
Group1
X±SD
Group2
X±SD
P-value
Thickness (mm)
Phalanx
1.80±0.354
2.35±0.39
Hand
1.58±0.20
2.22±0.40
Forearm
1.58±0.24
2.29 ±0.49
Leg
1.42±0.23
2.13±0.45
Chest
1.48±0.22
2.21±0.42
Echogenicity (pixels)
Phalanx
26.73±5.70
20.20±2.11
Hand
31.26±5.20
24.53±3.66
forearm
34.53±3.54
26.20±4.63
Leg
31.66±5.91
25.46±3.85
Chest
42.33±3.58
30.06±6.36
Skin hardness
23.86±4.42
30.60±3.20
X=mean, SD=Standard Deviation P-value=Probability level *highly significant (P<0.05).
0.000*
0.000*
0.000*
0.000*
0.000*
0.001*
0.000*
0.000*
0.002*
0.000*
0.000*
Group 1
Thickness of skin
(mm)
2.5
Group 2
2
1.5
1
0.5
0
Phalanx
Hand
Forearm
Leg
Chest
Fig. (1): Comparative analysis of the mean differences of skin thickness between both groups post-treatment.
Group 1
Echogenicity (pixel)
50
Group 2
40
30
20
10
0
Phalanx
Hand
Forearm
Leg
Chest
Fig. (2): Comparative analysis of the mean differences of echogenicity between both groups post-treatment.
Bull. Fac. Ph. Th. Cairo Univ., Vol. 16, No. (1) Jan. 2011
87
Skin hardness
(DU)
40
30
20
10
0
Group 1
Group 2
Fig. (3): Comparative analysis of the mean differences of skin hardness between both groups post-treatment.
DISCUSSION
Localized scleroderma (LS) is the most
common form of scleroderma in the pediatric
age range. For both systemic sclerosis and LS,
there is an initial inflammatory phase followed
by the replacement of normal tissue structures
by abnormal collagen29. Although scleroderma
refers to hardening of the skin, pediatric LS
often affects deeper tissue, including muscle,
bone, and some internal organs14. Because
active disease can persist for years, growing
children are at risk for major morbidity
including joint contractures, limb length
discrepancy, and facial atrophy20,26.
Various therapies for morphea have been
used with limited success, including ones with
potentially hazardous side effects. Recent
studies suggest that ultraviolet UVA1
phototherapy is an effective treatment for
localized scleroderma (LS); however, the
optimum UVA1 dose remains to be
determined4.
This study was conducted to compare
the effectiveness of medium dose versus low
dose UVA1 in childhood morphea. Patients
were divided into two groups of equal number,
group 1: received medium dose (40 J/cm2)
UVA1, while group 2: received Low-dose (20
J/cm2) UVA1. The frequency of treatment
was three times a week for 10 weeks.
Results of study showed that there was
significant difference for both groups post
treatment as regard to the thickness,
echogenicity and skin hardness, this confirm
the effectiveness of UVA1 for the treatment of
morphea whatever the dose. The effectiveness
of UVA1 may attributed to facilitation of the
induction of interstitial collagenase enzyme
that prevent the accumulation of collagen
which is the main pathology of LS or
morphea.
The results of this study were in
agreement with Kreuter; 200621 who reported
that there are three main pathways are
considered to contribute to the development of
LS: disturbance of collagen metabolism,
autoimmune activity, and vascular alteration.
UVA exhibits its effects in all of these 3
directions by up-regulation of specific
messenger RNA of matrix metalloproteinase,
depletion of skin – infiltrating T cells and
proinflammatory cytokines ( IL-1, IL-6 ),
induction of a shift of the balance between
proto-oncogenes and tumor suppressor genes
toward the induction of apoptosis, and
modulation of endothelial
regulation⁄
transformation. Also they stated that UVA1
wave lengths penetrate deeper into the skin
than do UVA2 and UVB wave lengths and
therefore, might be able to initiate more
collagenase activity.
Breuckmann et al., 20014 reported that a
shift of the balance between protooncogenes
(e.g., bcl-2) and tumor suppressor genes (e.g.,
p53) towards the induction of apoptosis seems
to be one of the major effects of UVA1
irradiation.
Hyun, et al., 200618 mentioned that
Transforming growth factor beta (TGF-beta)
plays a central role in the pathogenesis of
sclerotic skin diseases. Recently, special
attention was contributed to a family of
transcription factor proteins involved in TGFbeta signal transduction from cell surface to
the nucleus, the so-called SMADs. Ultraviolet
(UV) irradiation has been reported to alter
TGF-beta/SMAD pathway in human skin.
Also Scharffetter, et al., 199136 reported that
Ultraviolet Al (UVA1; 340-400 nm) radiation
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
88
is associated with induction of collagenase in
fibroblasts of lesional skin.
The results of the study also showed that
there were significant differences between
both groups (medium and low dose group) as
regard to thickness, echogenicity and skin
hardness post-treatment. This may attributed to
the cumulative dose of group 1 was double of
the cumulative dose of group 2 (1200 J⁄cm2
versus 600 J⁄cm2) and the induction of
collagenase enzyme is a dose dependant. So
more activity of collagenase enzyme and
improvement of disease in medium dose group
was more than low dose.
These results were in agreement with
Sator., et al., 200935 who concluded that
medium-dose provides for better long-term
results than low-dose UVA1 in LS as shown
by ultrasound assessment but with clinical
scoring, no significant difference between the
two UVA1 dose regimens was detected,
indicating that ultrasound measurement is a
more sensitive method for quantifying
treatment-induced skin changes in patients
with LS.
Kreuter, et al., 200621 reported that
Medium-dose UVA1 gives favorable results in
a shorter period of time as compared to lowdose UVA1 therapy, where a minimum of 3
months exposure is needed to obtain clinical
results.
Also Stege, et al., 199738 mentioned that
The mechanism of action of UVA 1 on
sclerotic skin is still not elucidated, although
previous reports showed a dose-dependent up
regulation of collagenase activity, which could
be responsible for the softening of the skin.
Camacho; et al., 20015 stated that
Medium-dose UVA1 therapy is effective in the
treatment of localized morphea. Effectiveness
is associated with an increase in the number of
CD34+ dendritic cells in the dermis.
On conclusion, medium dose UVA1 is
more effective than low dose UVA1 in the
treatment of childhood morphea.
REFERENCES
1- Aghassi, D., Monoson, T. and Braverman, I.:
Reproducible measurements to quantify
cutaneous involvement in scleroderma. Arch
Dermatol; 131: 1160-1166, 1995.
2- Athreya, B.H.: Juvenile scleroderma. Current
Opinion in Rheumatology, 14: 553-561, 2002.
3- Bono, W. and Dupin, N.: Localized
scleroderma (morphea). Presse Med.; 35:
1923-1928, 2006.
4- Breuckmann, F., Pieck, C., Kreuter, A.,
Bacharach-Buhles, M., Mannherz, H.G.,
Altmeyer, P. and von Kobyletzki, G.:
Opposing effects of UVA1 phototherapy on the
expression of bcl-2 and p53 in atopic
dermatitis. Arch Dermatol Res.; 293: 178-183,
2001.
5- Camacho,
N.R., Sánchez,
J.E., Martin,
R.F., González, J.R. and Sánchez, J.L.:
Medium-dose UVA1 phototherapy in localized
scleroderma and its effect in CD34-positive
dendritic cells. J Am Acad Dermatol.; 45(5):
697-699, 2001.
6- Cassidy, J.T. and Petty, R.E.: The sclerodermas
and related disease. In: Textbook of Pediatrics
Rheumatology,
4th
ed,
Philadelphia,
Pennsylvania, W.B. Saunders, 505-541, 2001.
7- Clements, P.J.: Measuring disease activity and
severity
in
scleroderma. Curr
Opin
Rheumatol; 7: 517-521, 1995.
8- Denton, C.P. and Derrett-Smith, E.C.:
Juvenile-onset systemic sclerosis: children are
not small adults. Rheumatology; 48-96, 2009.
9- El-Mofty, M., Mostafa, W., El-Darouty, M.,
Bosseila, M., Nada, H., Yousef, R., Esmat, S.,
El-Lawindy, M., Assaf, M. and El-Enani, G.:
Different low doses of broad-band UVA in the
treatment of morphea and systemic sclerosis.
Photodermatol Photoimmunol Photomed.;
20(3): 148-156, 2004.
10- El-Zawahry, M.B., Abdel El-Hameed ElCheweikh, H.M., Abd-El-Rahman Ramadan,
S., Ahmed Bassiouny, D. and Mohamed
Fawzy, M.: Ultrasound biomicroscopy in the
diagnosis of skin diseases. Eur J Dermatol.;
17(6): 469-475, 2007.
11- Falanga, V. and Bucalo, B.: Use of a durometer
to assess skin hardness. J Am Acad Dermatol;
29: 47–51, 1993.
12- Fett, N. and Werth, V.P.: Update on morphea:
part II. Outcome measures and treatment.. J
Am Acad Dermatol.; 64(2): 231-42; 243-244,
2011.
13- Fornage, B.D., McGavran, M.H. and Duvic,
M.: Imaging of the skin with 20 MHz
ultrasound. Radiology.; 189: 69-76, 1993.
14- Gruss, C., Reed, J.A., Altmeyer, P., McNutt,
N.S. and Kerscher, M.: Induction of interstitial
collagenase (MMP-1) by UVA-1 phototherapy
in morphea fibroblasts. Lancet.; 350: 12951296, 1997.
Bull. Fac. Ph. Th. Cairo Univ., Vol. 16, No. (1) Jan. 2011
15- Hawk, A. and English, J.C.: Localized and
systemic scleroderma. Semin Cutan Med
Surg.; 20(1): 27-37, 2001.
16- Hayakawa, I., Hasegawa, M., Takehara, K. and
Sato, S.: "Anti-DNA topoisomerase IIalpha
autoantibodies in localized scleroderma".
Arthritis Rheum. 50(1): 227-232, 2004.
17- Hunzelmann, N., Scharffetter Kochanek, K.,
Hager, C. and Krieg, T.: Management of
localized scleroderma. Semin Cutan Med
Surg.; 17(1): 34-40, 1998.
18- Hyun, J., Kreuter, A., Skrygan, M., Sommer,
A., Tomi, N.S., Breuckmann, F. and Altmeyer,
P.: Gambichler Ultraviolet A1 phototherapy
decreases inhibitory SMAD7 gene expression
in localized scleroderma. Arch Dermatol Res.;
298(6): 265-272, 2006.
19- Kesson, A., Hesselstrand, R., Scheja, A. and
Wildt, M.: Longitudinal development of skin
involvement and reliability of high frequency
ultrasound in systemic sclerosis Ann Rheum;
63: 791-796, 2004.
20- Kreuter, A., Gambichler, T., Avermaete,
A., Jansen, T., Hoffmann, M., Hoffmann,
K., Altmeyer,
P., von
Kobyletzki,
G.
and Bacharach-Buhles,
M.:
Combined
treatment with calcipotriol ointment and lowdose ultraviolet A1 phototherapy in childhood
morphea. Pediatr Dermatol.; 18(3): 241-245,
2001.
21- Kreuter, A., Hyun, J., Stücker, M., Sommer,
A., Altmeyer, P. and Gambichler, T.: A
randomized controlled study of low-dose
UVA1, medium-dose UVA1, and narrowband
UVB phototherapy in the treatment of
localized scleroderma. J Am Acad Dermatol.;
54(3): 440-447, 2006.
22- Kroft, E.B., van de Kerkhof, P.C., Gerritsen,
M.J. and de Jong, E.M.: Period of remission
after treatment with UVA-1 in sclerodermic
skin diseases. J Eur Acad Dermatol Venereol.;
22(7): 839-844, 2008.
23- Laxer, R. and Zulian, F.: Localized
scleroderma (LS). Curr Opin Rheumatol; 18:
606-613, 2006.
24- Li, S.C. and Liebling, M.S.: The use of
Doppler ultrasound to evaluate lesions of
localized scleroderma. Curr Rheumatol Rep.;
11(3): 205-211, 2009.
25- Li, S.C., Liebling, M.S., Haines, K.A., Weiss,
J.E. and Prann, A.: Initial evaluation of an
ultrasound measure for evaluating the activity
of skin lesions in pediatric localized
scleroderma. Arthritis Care Res (Hoboken),
2010.
26- Mempel, M., Schmidt, T., Boeck, K.,
Brockow, K., Stachowitz, S., Fesq, H., Schafer,
89
T., Thomsen, S., Schnopp, C., Ring, J., Probst,
R., Luppa, P. and Abeck, D.: Changes in
collagen I and collagen III metabolism in
patients with generalized atopic eczema
undergoing medium-dose ultraviolet A1
phototherapy. Br J Dermatol.; 142: 473-480,
2000.
27- Merkel,
P.A., Silliman,
N.P., Denton,
C.P., Furst, D.E., Khanna, D., Emery, P., Hsu,
V.M., Streisand,
J.B., Polisson,
R.P.
and Akesson, A.: Validity, reliability, and
feasibility of durometer measurements of
scleroderma skin disease in a multicenter
treatment trial. Arthritis Rheum; 59(5): 699705, 2008.
28- Monika-Hildegard, Schmid-Wendtner, M.D.
and Walter Burgdorf, M.D.: Ultrasound
Scanning in Dermatology; Arch Dermatol.;
141: 217-224, 2005.
29- Petersen, M., Hamilton, T. and Li, H.L.:
Regulation and inhibition of collagenase
expression by long-wavelength ultraviolet
radiation in cultured human skin fibroblasts.
Photochem Photobiol.; 62: 444–448, 1995.
30- Peterson, L.S., Nelson, A.M., Su, W.P.,
Mason, T., O'Fallon, W.M. and Gabriel, S.E.:
"The epidemiology of morphea (localized
scleroderma) in Olmsted County 1960-1993".
J. Rheumatol. 24(1): 73–80, 1997.
31- Preliminary criteria for the classification of
systemic
sclerosis
(scleroderma).
Subcommittee for scleroderma criteria of the
American Rheumatism Association Diagnostic
and Therapeutic Criteria Committee. Arthritis
Rheum.; 23(5): 581-90, 1980.
32- Rose, N.R. and Leskovsek, N.: Scleroderma:
immunopathogenesis and treatment. Immunol
Today; 19: 499-501, 1998.
33- Rosenkranz, M.E., Agle, L.M., Efthimiou, P.
and Lehman, T.J.: Systemic and localized
scleroderma in children: current and future
treatment options. Paediatr Drugs.; 8(2): 85-97,
2006.
34- Sandra, E.B. and Heidi, T.J.: Ultrasound as an
outcome measure to assess disease activity in
disorders of skin thickening: an example of the
use of radiologic techniques to assess skin
disease, Dermatologic Therapy; 20(2): 86-92,
2007.
35- Sator,
P.G., Radakovic,
S., Schulmeister,
K., Hönigsmann, H. and Tanew, A.: Mediumdose is more effective than low-dose ultraviolet
A1 phototherapy for localized scleroderma as
shown by 20-MHz ultrasound assessment. J
Am Acad Dermatol.; 60(5): 786-791, 2009.
36- Scharffetter, K., Wlaschek, M., Hogg, A.,
Bolsen, K., Schothorst, A. and Goerz, G.: UVA
Efficacy of Medium Versus Low Dose Ultraviolet A1 in the
Treatment of Childhood Localized Scleroderma (Morphea)
90
irradiation induces collagenase in human
dermal fibroblasts in vitro and in vivo. Arch
Dermatol Res; 283: 506-511, 1991.
37- Seyger, M.M., van den Hoogen, F.J., de Boo,
T. and de Jong, E.M.: Reliability of two
methods to assess morphea: Skin scoring and
the use of a durometer. J Am Acad Dermatol;
37: 793-796, 1997.
38- Stege, H., Berneburg, M., Humke, S.,
Klammer, M., Grewe, M. and Grether-Beck,
S.: High-dose UVA1 radiation therapy for
localized scleroderma. J Am Acad Dermatol;
36: 938-944, 1997.
39- Vierra, E. and Cunningham, B.B.: Morphea
and localized scleroderma in children. Semin
Cutan Med Surg.; 18(3): 210-225, 1999.
40- Yin, L., Yamauchi, R., Tsuji, T., Krutmann, J.
and Morita, A.: The expression of matrix
metalloproteinase-1 mRNA induced by
ultraviolet A1 (340–400 nm) is phototherapy
relevant to the glutathione (GSH) content in
skin fibroblasts of systemic sclerosis. J
Dermatol.; 30: 173-180, 2003.
41- Zancanaro, P.C., Isaac, A.R., Garcia, L.T. and
Costa, I.M.: Localized scleroderma in children:
clinical, diagnostic and therapeutic aspects. An
Bras Dermatol.; 84(2): 161-172, 2009.
42- Zulian, F., Athreya, B.H. and Laxer, R.:
"Juvenile localized scleroderma: clinical and
epidemiological features in 750 children. An
international study". Rheumatology (Oxford);
45(5): 614–620, 2006.
43- Zulian, F.: New developments in localized
scleroderma. Curr Opin Rheumatol.; 20(5):
601-707, 2008.
الملخص العربي
كفاءة الجرعة المتوسطة مقارنة بالجرعة المنخفضة
من األشعة فوق البنفسجية ذات المدى الطويل (أ) في عالج تصلب الجلد عند األطفال
يهدف هذا البحث إلي دراسة كفاءة الجرعة المتوسطة من األشعة فوق البنفسجية ذات المدى الطويل (أ) مقارنة بالجرعة المنخفضة في عالج
. سنة ممن يعانون من تصلب الجلد13 إلي6 وقد أجريت هذه الدراسة علي ثالثين مريضا تتراوح أعمارهم بين. تصلب الجلد عند األطفال
تلقت جرعة متوسطة من األشعة فوق البنفسجية ذات: ) 1 ( المجموعة األولي. وقد تم تقسيمهم عشوائيا إلي مجموعتين متساويتين في العدد
تلقت جرعة منخفضة من: ) 2 ( أسابيع بينما المجموعة الثانية10 جلسات أسبوعيا وذلك لمدة3 ) بواقع40 J/cm2( )المدى الطويل (أ
وقد تم قياس سمك. أسابيع أيضا10 جلسات أسبوعيا وذلك لمدة3 ) بواقع20 J/cm2 ( )األشعة فوق البنفسجية ذات المدى الطويل (أ
وقد أظهرت النتائج فروق ذات داللة إحصائية بين المجموعتين بعد. أسابيع للمجموعتين10 وصدوية الجلد وأيضا صالبة الجلد قبل وبعد
العالج بالنسبة لسمك وصدوية الجلد وأيضا صالبة الجلد و يمكن أن نستخلص أن كفاءة الجرعة المتوسطة من األشعة فوق البنفسجية ذات
. المدى الطويل (أ) أكبر مقارنة بالجرعة المنخفضة في عالج تصلب الجلد عند األطفال
سمك، تصلب الجلد عند األطفال، الجرعة المنخفضة، الجرعة المتوسطة، ) األشعة فوق البنفسجية ذات المدى الطويل (أ: الكلمات الدالة
. ديوروميتر، دوبلر الموجات فوق الصوتية، صالبة الجلد، صدوية الجلد، الجلد